Givinostat, commercialized under the brand name Duvyzat, is a unique pharmacological agent predominantly utilized for the therapeutic management of Duchenne muscular dystrophy. As a histone deacetylase inhibitor, Givinostat flaunts noteworthy anti-inflammatory, anti-angiogenic, and antineoplastic potential. The drug works via selective hindrance of histone deacetylase (HDAC) isoforms, which in turn develops an accumulation of acetylated histones, affecting the transcription of various genes causing cellular differentiation and apoptosis.
Parent: Givinostat
The preparation of Givinostat, like other pharmaceuticals, also involves the possibility of generating impurities. These impurities can exist independently or be related compounds to the original drug moiety. An impurity or a conglomerate of multiple impurities in Givinostat may impact its efficacy or patient tolerance, thereby necessitating proper characterization and quantification of these impurities. Owing to the sophisticated technique involved in the drug synthesis, potential impurities could include unreacted precursors, metabolites or degradation products.
Givinostat is primarily used for the treatment of Duchenne muscular dystrophy. It can modify the course of disease progression by inhibiting histone deacetylase enzymes leading to anti-inflammatory, anti-angiogenic, and antineoplastic activity.
No, Givinostat is not a gene therapy. It is a histone deacetylase inhibitor and works on modifying the way certain genes in cells are transcribed.
As of now, Givinostat for the treatment of Duchenne muscular dystrophy has not received FDA approval. It’s currently under clinical investigation.
One unique feature of Givinostat is its multi-faceted mechanism of action. It is an anti-inflammatory, anti-angiogenic, and anti-neoplastic agent, with potential to modify the course of Duchenne muscular dystrophy.
